Healthcare provider profile · identity verified

Luise Weinstein, MD

Internal Medicine · NEW YORK, NY · NPI 1952498024

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	303	103
Amlodipine Besylate	Amlodipine Besylate	270	102
Losartan Potassium	Losartan Potassium	137	50
Levothyroxine Sodium	Levothyroxine Sodium	111	41
Metoprolol Succinate	Metoprolol Succinate	102	34
Gabapentin	Gabapentin	91	28
Rosuvastatin Calcium	Rosuvastatin Calcium	91	38
Omeprazole	Omeprazole	87	30
Albuterol Sulfate Hfa	Albuterol Sulfate	86	20
Lisinopril	Lisinopril	82	30
Ozempic	Semaglutide	82	19
Simvastatin	Simvastatin	80	29
Eliquis	Apixaban	75	21
Metformin Hcl	Metformin Hcl	67	27
Hydrochlorothiazide	Hydrochlorothiazide	59	23
Metformin Hcl Er	Metformin Hcl	56	21
Atenolol	Atenolol	50	16
Tamsulosin Hcl	Tamsulosin Hcl	50	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	18
Carvedilol	Carvedilol	42	19
Mounjaro	Tirzepatide	42	11
Fluticasone Propionate	Fluticasone Propionate	41	15
Pantoprazole Sodium	Pantoprazole Sodium	41	16
Diclofenac Sodium	Diclofenac Sodium	40	18
Jardiance	Empagliflozin	40	14
Pravastatin Sodium	Pravastatin Sodium	37	12
Ezetimibe	Ezetimibe	36	15
Escitalopram Oxalate	Escitalopram Oxalate	34	12
Trulicity	Dulaglutide	33	suppressed
Alendronate Sodium	Alendronate Sodium	32	12
Montelukast Sodium	Montelukast Sodium	32	suppressed
Valsartan	Valsartan	30	12
Januvia	Sitagliptin Phosphate	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	29	suppressed
Famotidine	Famotidine	26	12
Symbicort	Budesonide/Formoterol Fumarate	26	suppressed
Prednisone	Prednisone	25	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Ammonium Lactate	Ammonium Lactate	23	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Furosemide	Furosemide	19	14
Lorazepam	Lorazepam	19	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Trazodone Hcl	Trazodone Hcl	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Meloxicam	Meloxicam	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Allopurinol	Allopurinol	14	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	14	14
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Cyclosporine	Cyclosporine	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Finasteride	Finasteride	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Repaglinide	Repaglinide	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error